These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 35905827)
1. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group. Janez A; Muzurovic E; Stoian AP; Haluzik M; Guja C; Czupryniak L; Duvnjak L; Lalic N; Tankova T; Bogdanski P; Papanas N; Nunes JS; Kempler P; Fras Z; Rizzo M Int J Cardiol; 2022 Oct; 365():8-18. PubMed ID: 35905827 [TBL] [Abstract][Full Text] [Related]
2. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect? Li Y; Rosenblit PD Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. Goldman JD J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety and benefits of GLP-1 receptor agonists. Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093 [TBL] [Abstract][Full Text] [Related]
14. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. Patel D J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489 [TBL] [Abstract][Full Text] [Related]
15. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials. Urquhart S; Willis S JAAPA; 2020 Aug; 33(8):19-30. PubMed ID: 32740122 [TBL] [Abstract][Full Text] [Related]
17. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials. Al Yami MS; Alfayez OM; Alsheikh R Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418 [TBL] [Abstract][Full Text] [Related]
18. [A new era for glucagon-like peptide-1 receptor agonists]. Neuville MF; Paquot N; Scheen AJ Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066 [TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Gentilella R; Pechtner V; Corcos A; Consoli A Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747 [TBL] [Abstract][Full Text] [Related]
20. Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus. Eghbali M; Alaei-Shahmiri F; Hashemi-Madani N; Emami Z; Mostafavi L; Malek M; Khamseh ME Adv Ther; 2024 Feb; 41(2):826-836. PubMed ID: 38172377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]